

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 December 2024 (19.12.2024)



(10) International Publication Number
WO 2024/259322 A1

(51) International Patent Classification:

C07C 237/06 (2006.01) C07D 295/15 (2006.01)
C07C 237/22 (2006.01) A61K 9/127 (2006.01)

(21) International Application Number:

PCT/US2024/034127

(22) International Filing Date:

14 June 2024 (14.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/508,772 16 June 2023 (16.06.2023) US

(71) Applicant: **ACUITAS THERAPEUTICS, INC.**
[CA/CA]; 6190 Agronomy Road, Suite 405, Vancouver,
British Columbia V6T 1Z3 (CA).

(72) Inventors: **TAN, Jason Samuel**; c/o Acuitas Therapeu-
tics, Inc., 6190 Agronomy Road, Suite 405, Vancouver,
British Columbia V6T 1Z3 (CA). **ARNS, Stephen Paul**;
c/o Acuitas Therapeutics, Inc., 6190 Agronomy Road,
Suite 405, Vancouver, British Columbia V6T 1Z3 (CA).
GATENYO, Julia; c/o Acuitas Therapeutics, Inc., 6190
Agronomy Road, Suite 405, Vancouver, British Columbia
V6T 1Z3 (CA). **YEREMY, Benjamin**; c/o Acuitas Thera-
peutics, Inc., 6190 Agronomy Road, Suite 405, Vancouver,
British Columbia V6T 1Z3 (CA).

(74) Agent: **LIGON, Toby J.** et al.; Seed Intellectual Proper-
ty Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle,
Washington 98104-7064 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,


NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: LIPIDS FOR USE IN LIPID NANOPARTICLES



(I)

(57) Abstract: Compounds are provided having the following Formula (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R^1 , R^2 , R^3 , G^1 , G^2 , L^1 , and L^2 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.



WO 2024/259322 A1